The development of a cure for diabetes and its complications is estimated to require at least ¥300 million (approximately $2 million) over the next three years to maintain the current research infrastructure. Additionally, for next-generation, side-effect-free cell-targeting technology-based drugs, the basic technology development alone is expected to cost around ¥2 billion (approximately $13 million). This includes expenses for experimental materials, equipment, personnel, and clinical trials.

The total cost of developing a new drug for human use, including clinical trials, typically ranges from tens of billions to over ¥100 billion (hundreds of millions of dollars). To secure the necessary funding for research, clinical trials, and regulatory approval, Biozipcode, Inc. is exploring multiple avenues, including investment from investors, government and private grants, and joint research through strategic partnerships. Efficient fundraising and resource optimization are essential for the success of new drug development.

Studio Makyu Co., Ltd. is actively working to build a strong support system for developing a complete cure for diabetes. In addition to crowdfunding, we are pursuing various funding strategies and resource optimization approaches from multiple perspectives to accelerate this mission.